CUROSURF® (poractant alfa) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only.
CUROSURF is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.
Media Articles Related to Curosurf (Poractant Alfa)
ARDS (Acute Respiratory Distress Syndrome)
Source: MedicineNet Endotracheal Intubation Specialty [2012.01.20]
Title: ARDS (Acute Respiratory Distress Syndrome)
Category: Diseases and Conditions
Created: 3/12/2007 12:00:00 AM
Last Editorial Review: 1/20/2012 12:00:00 AM
Predictors of Survival in Critically Ill Patients With ARDS
Source: Medscape Anesthesiology Headlines [2017.01.10]
Which parameters can most accurately predict outcome in critically ill patients with acute respiratory distress syndrome?
Published Studies Related to Curosurf (Poractant Alfa)
A Randomized, Controlled Trial of Poractant Alfa versus Beractant in the Treatment of Preterm Infants with Respiratory Distress Syndrome. [2011.11.21]
We prospectively evaluated the differences in clinical responses and short-term outcomes in preterm infants with respiratory distress syndrome (RDS) treated with poractant alfa or beractant. Premature infants with RDS were randomized to poractant alfa or beractant treatment between July 2008 and June 2009...
Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. [2010.10]
OBJECTIVE: Comparison of the differences between availability of animal-derived surfactant preparations used to treat premature infants is incomplete. The objective of this study was to assess the short-term treatment efficacy of the two most commonly used surfactant preparations in the United States, beractant (100 mg kg(-1) initial and subsequent doses) and poractant alfa (200 mg kg(-1) initial and 100 mg kg(-1) subsequent doses), in very premature, mechanically ventilated infants <30 weeks gestation with respiratory distress syndrome (RDS)... CONCLUSION: This study suggests significant short-term benefits to the use of the larger initial dose of poractant alfa than beractant in very premature infants with RDS. Further studies involving a larger number of preterm infants are needed to assess long-term effects.
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. [2005.06]
AIM: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS)... CONCLUSIONS: Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. [2005.04]
BACKGROUND: Available therapeutic surfactants are either animal-derived or non-protein-containing synthetic products. Animal-derived surfactants contain variable amounts of surfactant apoproteins, whereas the older-generation synthetic products contain only phospholipids and lack surfactant proteins (SPs). Both decrease morbidity and mortality rates associated with respiratory distress syndrome (RDS) among preterm infants, compared with placebo. However, excess mortality rates have been observed with non-protein-containing synthetic surfactants, compared with the animal-derived products. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved with the addition of peptides that are functional analogs of SPs. Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B. It is completely devoid of animal-derived components. OBJECTIVE: We hypothesized that the outcomes for premature infants treated with lucinactant and poractant alfa would be similar. Therefore, we compared lucinactant (Surfaxin; Discovery Laboratories, Doylestown, PA) with porcine-derived, poractant alfa (Curosurf; Chiesi Farmaceutici, Parma, Italy) in a trial to test for noninferiority... CONCLUSIONS: Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants. The ability to enhance the performance of a synthetic surfactant with the addition of a peptide that mimics the action of SP-B, such as sinapultide, brings potential advantages to exogenous surfactant therapy.
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. [2004.04]
We compared the onset of clinical response and safety of two surfactants, poractant alfa (Curosurf, Chiesi Pharmaceuticals, Parma, Italy) and beractant (Survanta, Ross Laboratories, Columbus, OH), for treatment of respiratory distress syndrome (RDS) in preterm infants weighing 750 to 1750 g at birth and <35 weeks gestation...
Clinical Trials Related to Curosurf (Poractant Alfa)
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants [Terminated]
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome
(RDS) in premature infants greatly improved survival rates. Newer surfactants approved by
the FDA were more concentrated and had a more rapid onset of action. The overall efficacy of
newer surfactants appeared similar until in 2004, Ramanathan and colleagues suggested that a
double dose of Curosurf improved survival in infants 25-32 weeks gestational age, compared
to infants treated with Survanta, the most commonly used surfactant preparation in the
United States. While the data was suggestive, it was not clear that the improvement in
survival was reproducible or that Curosurf was responsible for the improved survival rates.
The purpose of this study was to investigate the role of Curosurf in improving lung function
and survival rates and reducing the complications of prematurity in very premature infants <
30 weeks gestational age at birth.
A Multi-center Trial to Determine if Curosurf� Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 29+6 Weeks Gestational Age [Recruiting]
The purpose of this study is to see if a medication called Curosurf can reduce the length of
time that small premature babies with Respiratory Distress Syndrome (immature lungs) or RDS,
stay on the ventilator, as compared to the standard medication called BLES. Curosurf is a
medication that is already used in other countries around the world but not yet in Canada.
Babies born under 30 weeks of gestation frequently need respiratory support after birth,
including being placed on a breathing machine or respirator. The most common reason is
Respiratory Distress Syndrome (RDS) whereby immature lungs don't produce enough surfactant,
a soapy like substance that helps the air sacs open and close. Our current standard
treatment is a surfactant called BLES. Curosurf contains more active ingredient per volume
therefore the amount is smaller. The investigators hypothesize that babies who receive
Curosurf will be able to be removed from the ventilator sooner.
Babies in this study will have a 50/50 chance of receiving either Curosurf or BLES and the
investigators will monitor their progress during their Neonatal Intensive Care Unit
The study is taking place in Canada. The goal is to enroll 88 babies. There are no extra
tests (blood tests or X-Rays) or return visits to the hospital for the purposes of this
Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome [Withdrawn]
This is a null hypothesis study. The investigators hypothesize that there will be no
difference in changes in dynamic compliance when measured at 15, 30, 45 and 60 minute
intervals after administration of either surfactant and there will be no differences in the
number of doses needed between the two surfactants in premature infants admitted to our
Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study [Completed]
The primary objective of this study is to compare two methods of post-delivery stabilization
and subsequent early respiratory care for reducing the need for MV and related secondary
complications, such as BPD, in premature babies at high risk of RDS:
1. Early stabilization on nCPAP
2. Intubation, prophylactic surfactant (Curosurf®) administration shortly after delivery,
and rapid extubation to nCPAP.
The data obtained from this comparison will be applied to test the hypothesis that preterm
neonates at risk of RDS who are treated with prophylactic surfactant + nCPAP show less need
for MV when compared to infants who receive nCPAP alone.
Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage [Completed]
The incidence of pulmonary hemorrhage (PH) was about 1. 3 per 1,000 live births. PH occurs
mainly in preterm ventilated infants with severe respiratory distress syndrome (RDS) who
often have a PDA and have received surfactant. Although not clear, the cause of PH is
thought to be due to a rapid lowering of intrapulmonary pressure, which facilitates left to
right shunting across a patent ductus arteriosus and an increase in pulmonary blood flow.
Prospective uncontrolled studies that used surfactant for PH in neonates have shown
promising results in treating PH. In this study we aimed to evaluate the effect of two
different natural surfactants in neonates with pulmonary hemorrhage.
Reports of Suspected Curosurf (Poractant Alfa) Side Effects
C-Reactive Protein Increased (4),
Pulmonary Haemorrhage (4),
Drug Ineffective (3),
Oxygen Saturation Decreased (3),
Disseminated Intravascular Coagulation (2),
Expired Drug Administered (2),
Product Quality Issue (2), more >>
Page last updated: 2017-01-10